DIAPH2 and pancreatic adenocarcinoma: The genetic alteration profiles of PAAD in TCGA dataset and four selected studies showed that 1.1% of the enrolled patients had DIAPH1 genetic alterations, 1.1% had DIAPH2 genetic alterations (predominantly missense mutations), and 0.9% had DIAPH3 genetic alterations (Figures 2A–C).